Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
This Gs-biased profile may contribute to sustained receptor signaling with less desensitization, though the clinical implications of signaling bias in GLP-1 therapeutics remain an area of active investigation
FDA-approved as Mounjaro (for type 2 diabetes) and Zepbound (for obesity), tirzepatide's dual mechanism enhances insulin sensitivity through GIP receptors while suppressing appetite through GLP-1 receptors
Long-term commitment: It is important to recognize that GLP-1 agonists are not a magic bullet
The heterogeneity of type 1 diabetes: implications for pathogenesis, prevention, and treatment2024 diabetes, diabetes care, and diabetologia expert forum
US$ 29.25
US$ 22.23
US$ 20.83
US$ 20.03
US$ 28.59
US$ 29.01
US$ 22.37
US$ 24.85
US$ 25.39
US$ 22.57
US$ 22.85
US$ 28.33
